Webcast ImageWebcast
Audentes Therapeutics Inc at Wedbush PacGrow Healthcare Conference (Live)
08/15/17 at 12:45 p.m. ET
Audentes Therapeutics Inc at Wedbush PacGrow Healthcare Conference
Tuesday, August 15, 2017 12:45 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Audentes Therapeutics is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. We are a focused, experienced and passionate team driven by the goal of improving the lives of patients.

We currently have four products in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome, AT307 for the treatment of CASQ2-related Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), and AT982 for the treatment of Pompe disease.
Stock Information
BOLD (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 1.33 (0.00%)
Data as of 07/26/17 4:00 p.m. ET
Refresh quote
Stock chart for: BOLD.O.  Currently trading at $20.77 with a 52 week high of $22.82 and a 52 week low of $13.06.
Recent NewsMore >>
Audentes Therapeutics Announces Appointment of Fulvio Mavilio, Ph.D. to Vice President Scientific Affairs, Europe
Audentes Therapeutics Announces Participation in Upcoming Investor Conferences
Audentes Therapeutics Appoints Jennifer Jarrett to Board of Directors
Upcoming EventsMore >>
Tuesday, August 15, 2017 12:45 p.m. ET
Audentes Therapeutics Inc at Wedbush PacGrow Healthcare Conference

Primary IR Contact
Thomas Soloway
SVP and Chief Financial Officer
Audentes Therapeutics, Inc.
E-mail: ir@audentestx.com

Data provided by Nasdaq. Minimum 15 minutes delayed.